Wire · opportunities
Drugmakers and Research Partners Have Until October 30 to Apply for FDA Pilot Targeting ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 September 2026 · Fusion42 review
The FDA has launched its Expedited Investigational New Drug (IND) Pilot, accepting applications from drugmakers and research partners by October 30, 2026, to accelerate the timeline for first-in-human trials without changing safety or approval standards.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to prepare to partner with qualified research institutions now to meet the October 30 deadline and benefit from the FDA's rolling IND review designed to speed your early human trials. Slower trial start times are becoming less acceptable in the US, so missing this pilot could cost crucial time in competitive drug development.
◆ Coverage
1 source · 17 Sep 2026
◆ Related on Wire
◆ Topics